Posts Tagged ‘time’


    Loading...

  • Science Retracts Paper on XMRV-Chronic Fatigue Syndrome Link

    Friday, December 23rd, 2011 at 04:25 | Comments Off

    The journal Science has now fully retracted a paper it published in 2009 that linked chronic fatigue syndrome to the retrovirus XMRV.

    The editor-in-chief of the journal, Bruce Alberts, wrote that “multiple laboratories, including those of the original authors” have failed to duplicate the findings of the paper, which reported finding XMRV in a greater proportion of CFS patients than healthy controls. The study excited patients, who hoped the discovery would lead to possible treatments, and sparked public-health worries over possible ..read more

  • A.M. Vitals: Vertex CEO Emmens, Amgen CEO Sharer to Retire Next Year

    Saturday, December 17th, 2011 at 00:55 | Comments Off

    Drug-Company Changes: Matthew Emmens, the CEO of Vertex — which this year won approval for a hepatitis C drug — will leave that job Feb. 1 and will be replaced by Jeffrey Leiden, the WSJ reports. Emmens will become executive chairman through May, when he’ll retire but will remain a director of the company, the paper says. Meantime, Kevin Sharer will retire as Amgen’s CEO in May, the WSJ reports. He’ll be replaced by current president and ..read more

  • GAO Report Blames Drug Shortages On Manufacturing Problems

    Thursday, December 15th, 2011 at 15:59 | Comments Off

    Central to the drug-shortage issue is a chicken-and-egg question that often leaves legislators scratching their heads at congressional hearings.

    Chicken: Are the shortages of crucial drugs caused by factory flaws and shutdowns? Or egg: Are shortages somehow caused by economics, like the thin profit margins of generic drugs?

    A federal report to be released Thursday comes down with both feet in the chicken camp.

    “Manufacturing problems were the primary cause of most shortages,” says an analysis by the Government Accountability Office. And how ..read more

  • A.M. Vitals: Ranbaxy Launches Generic Lipitor in U.S.

    Friday, December 2nd, 2011 at 00:51 | Comments Off

    Generic Lipitor Approval: Indian drug company Ranbaxy, a unit of Japan’s Daiichi Sankyo, has received FDA approval for its generic version of Pfizer’s Lipitor, the WSJ reports. (Ranbaxy will share profits from the drug during the first 180 days with Teva, according to the company.) The FDA says Ranbaxy’s atorvastatin calcium tablets will be manufactured by Ohm Laboratories in New Jersey. Meantime, Watson Pharmaceuticals yesterday began selling a version of generic Lipitor authorized by, and in partnership ..read more

  • What Does the FDA’s Avastin Decision Mean for Breast Cancer Patients?

    Saturday, November 19th, 2011 at 05:13 | Comments Off

    The Food and Drug Administration’s decision to revoke approval of Roche’s Avastin for advanced breast cancer is likely to curtail use of the $6 billion-a-year drug for such patients. But it’s not likely to put an end to prescribing.

    Today’s action doesn’t affect the drug’s other approved uses, which include certain types of colon, lung, kidney and brain cancers, the FDA said. And physicians are free to prescribe an approved drug for any use they see fit.

    One question, ..read more

  • Not Just a Cheerleader: Foundation Helped Drive Cystic-Fibrosis Research

    Friday, October 21st, 2011 at 05:09 | Comments Off
    A young patient holds her experimental cystic fibrosis medication, Vertex’s Kalydeco.

    The WSJ reports today on the two-decade quest to develop drugs for cystic fibrosis following the discovery of the gene responsible for the respiratory disease.

    In addition to the scientific hurdles, a big challenge facing those seeking treatments was finding a company willing to make the investment. “Very few returned my call,” recalls Robert Beall, chief executive of the Cystic Fibrosis Foundation.

    The foundation ended up taking a role normally reserved for ..read more

  • Getting Lab Results Directly to Patients

    Tuesday, September 20th, 2011 at 01:27 | Comments Off

    A new federal proposal to give all patients in the U.S. direct electronic access to their lab results could make it easier to track important health markers like cholesterol levels and the body’s response to blood thinners – – with an iPhone.

    The rules proposed by the Dept. of Health and Human Services are part of a broader effort to give patients more access to their own medical data, so they can become more engaged in their care. They would replace ..read more

  • A.M. Vitals: Colorado Farm Recalling Cantaloupes on Listeria Fears

    Thursday, September 15th, 2011 at 22:43 | Comments Off

    Pulling Fruit: Colorado-based Jensen Farms is recalling cantaloupes sold between July 29 and Sept. 10 on fears that they might be tainted by listeria bacteria, the WSJ reports. A multi-state outbreak of listeriosis has sickened 16 people and killed one of them, but the FDA and Colorado public-health authorities have not indicated whether the farm’s cantaloupes are the source of the outbreak, the paper says.

    Left Off the List: The Joint Commission issued a list of 405 U.S. ..read more

  • Why One IOM Committee Member Dissented on Women’s Health Report

    Thursday, July 21st, 2011 at 04:40 | Comments Off

    The Institute of Medicine’s much-anticipated recommendations for which women’s health services should be covered by health plans without co-pays or deductibles came out yesterday. Among the eight services it recommends insurers cover at no extra charge — HHS will make the final decision — are all forms of approved contraception, breastfeeding support and breast-pump rentals and domestic-violence screening.

    One member of the committee charged with coming up with the recommendations, however, had several issues with how the report was developed — ..read more

  • A.M. Vitals: Research Review Links Pfizer’s Chantix to Heart Problems

    Tuesday, July 5th, 2011 at 22:28 | Comments Off

    Drug Study: A research review published by the Canadian Medical Association Journal finds that Pfizer’s anti-smoking drug Chantix is linked to a 72% increase in the risk of heart problems, the WSJ reports. A commentary authored by a physician who has received funding from Pfizer argues that a small drug-related risk is overshadowed by the cardiac benefits of smoking cessation.

    Test Overuse: A study published in Obstetrics and Gynecology finds physicians are screening women for HPV more frequently ..read more